Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Page: 70

Published Date: 13 Jan 2025

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at US$ 301 million in 2024 and is forecast to a readjusted size of USD 398 million by 2031 with a CAGR of 4.1% during review period.

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Idiopathic Pulmonary Fibrosis (IPF) Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:
Global Idiopathic Pulmonary Fibrosis (IPF) Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Idiopathic Pulmonary Fibrosis (IPF) Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Idiopathic Pulmonary Fibrosis (IPF) Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Idiopathic Pulmonary Fibrosis (IPF) Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Idiopathic Pulmonary Fibrosis (IPF) Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Idiopathic Pulmonary Fibrosis (IPF) Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche Holding AG, Boehringer Ingelheim International GmbH, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Idiopathic Pulmonary Fibrosis (IPF) Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Nintedanib
    Pirfenidone

Market segment by Application
    Hospital
    Clinics
    Others

Major players covered
    Roche Holding AG
    Boehringer Ingelheim International GmbH

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Idiopathic Pulmonary Fibrosis (IPF) Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, with price, sales quantity, revenue, and global market share of Idiopathic Pulmonary Fibrosis (IPF) Drug from 2020 to 2025.
Chapter 3, the Idiopathic Pulmonary Fibrosis (IPF) Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Idiopathic Pulmonary Fibrosis (IPF) Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Idiopathic Pulmonary Fibrosis (IPF) Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Idiopathic Pulmonary Fibrosis (IPF) Drug.
Chapter 14 and 15, to describe Idiopathic Pulmonary Fibrosis (IPF) Drug sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type: 2020 Versus 2024 Versus 2031
        1.3.2 Nintedanib
        1.3.3 Pirfenidone
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application: 2020 Versus 2024 Versus 2031
        1.4.2 Hospital
        1.4.3 Clinics
        1.4.4 Others
    1.5 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size & Forecast
        1.5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020 & 2024 & 2031)
        1.5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (2020-2031)
        1.5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price (2020-2031)

2 Manufacturers Profiles
    2.1 Roche Holding AG
        2.1.1 Roche Holding AG Details
        2.1.2 Roche Holding AG Major Business
        2.1.3 Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        2.1.4 Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.1.5 Roche Holding AG Recent Developments/Updates
    2.2 Boehringer Ingelheim International GmbH
        2.2.1 Boehringer Ingelheim International GmbH Details
        2.2.2 Boehringer Ingelheim International GmbH Major Business
        2.2.3 Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        2.2.4 Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.2.5 Boehringer Ingelheim International GmbH Recent Developments/Updates

3 Competitive Environment: Idiopathic Pulmonary Fibrosis (IPF) Drug by Manufacturer
    3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Manufacturer (2020-2025)
    3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Manufacturer (2020-2025)
    3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturer (2020-2025)
    3.4 Market Share Analysis (2024)
        3.4.1 Producer Shipments of Idiopathic Pulmonary Fibrosis (IPF) Drug by Manufacturer Revenue ($MM) and Market Share (%): 2024
        3.4.2 Top 3 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer Market Share in 2024
        3.4.3 Top 6 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer Market Share in 2024
    3.5 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Overall Company Footprint Analysis
        3.5.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Region Footprint
        3.5.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Type Footprint
        3.5.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region
        4.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2031)
        4.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2031)
        4.1.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2020-2031)
    4.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)
    4.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)
    4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)
    4.5 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)
    4.6 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)

5 Market Segment by Type
    5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)
    5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type (2020-2031)
    5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2020-2031)

6 Market Segment by Application
    6.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)
    6.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application (2020-2031)
    6.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2020-2031)

7 North America
    7.1 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)
    7.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)
    7.3 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country
        7.3.1 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)
        7.3.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)
        7.3.3 United States Market Size and Forecast (2020-2031)
        7.3.4 Canada Market Size and Forecast (2020-2031)
        7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe
    8.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)
    8.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)
    8.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country
        8.3.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)
        8.3.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)
        8.3.3 Germany Market Size and Forecast (2020-2031)
        8.3.4 France Market Size and Forecast (2020-2031)
        8.3.5 United Kingdom Market Size and Forecast (2020-2031)
        8.3.6 Russia Market Size and Forecast (2020-2031)
        8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific
    9.1 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)
    9.2 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)
    9.3 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region
        9.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2031)
        9.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2031)
        9.3.3 China Market Size and Forecast (2020-2031)
        9.3.4 Japan Market Size and Forecast (2020-2031)
        9.3.5 South Korea Market Size and Forecast (2020-2031)
        9.3.6 India Market Size and Forecast (2020-2031)
        9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
        9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America
    10.1 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)
    10.2 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)
    10.3 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country
        10.3.1 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)
        10.3.2 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)
        10.3.3 Brazil Market Size and Forecast (2020-2031)
        10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa
    11.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)
    11.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)
    11.3 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country
        11.3.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)
        11.3.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)
        11.3.3 Turkey Market Size and Forecast (2020-2031)
        11.3.4 Egypt Market Size and Forecast (2020-2031)
        11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
        11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics
    12.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers
    12.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints
    12.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Idiopathic Pulmonary Fibrosis (IPF) Drug and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Idiopathic Pulmonary Fibrosis (IPF) Drug
    13.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Distributors
    14.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
 Table 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Table 3. Roche Holding AG Basic Information, Manufacturing Base and Competitors
 Table 4. Roche Holding AG Major Business
 Table 5. Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
 Table 6. Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 7. Roche Holding AG Recent Developments/Updates
 Table 8. Boehringer Ingelheim International GmbH Basic Information, Manufacturing Base and Competitors
 Table 9. Boehringer Ingelheim International GmbH Major Business
 Table 10. Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
 Table 11. Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 12. Boehringer Ingelheim International GmbH Recent Developments/Updates
 Table 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Manufacturer (2020-2025) & (K Units)
 Table 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Manufacturer (2020-2025) & (USD Million)
 Table 15. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturer (2020-2025) & (US$/Unit)
 Table 16. Market Position of Manufacturers in Idiopathic Pulmonary Fibrosis (IPF) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
 Table 17. Head Office and Idiopathic Pulmonary Fibrosis (IPF) Drug Production Site of Key Manufacturer
 Table 18. Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Type Footprint
 Table 19. Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Application Footprint
 Table 20. Idiopathic Pulmonary Fibrosis (IPF) Drug New Market Entrants and Barriers to Market Entry
 Table 21. Idiopathic Pulmonary Fibrosis (IPF) Drug Mergers, Acquisition, Agreements, and Collaborations
 Table 22. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
 Table 23. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2025) & (K Units)
 Table 24. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2026-2031) & (K Units)
 Table 25. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2025) & (USD Million)
 Table 26. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2026-2031) & (USD Million)
 Table 27. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2020-2025) & (US$/Unit)
 Table 28. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2026-2031) & (US$/Unit)
 Table 29. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)
 Table 30. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)
 Table 31. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type (2020-2025) & (USD Million)
 Table 32. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type (2026-2031) & (USD Million)
 Table 33. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2020-2025) & (US$/Unit)
 Table 34. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2026-2031) & (US$/Unit)
 Table 35. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)
 Table 36. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)
 Table 37. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application (2020-2025) & (USD Million)
 Table 38. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application (2026-2031) & (USD Million)
 Table 39. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2020-2025) & (US$/Unit)
 Table 40. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2026-2031) & (US$/Unit)
 Table 41. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)
 Table 42. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)
 Table 43. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)
 Table 44. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)
 Table 45. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)
 Table 46. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)
 Table 47. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)
 Table 48. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)
 Table 49. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)
 Table 50. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)
 Table 51. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)
 Table 52. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)
 Table 53. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)
 Table 54. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)
 Table 55. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)
 Table 56. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)
 Table 57. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)
 Table 58. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)
 Table 59. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)
 Table 60. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)
 Table 61. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2025) & (K Units)
 Table 62. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2026-2031) & (K Units)
 Table 63. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2025) & (USD Million)
 Table 64. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2026-2031) & (USD Million)
 Table 65. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)
 Table 66. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)
 Table 67. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)
 Table 68. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)
 Table 69. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)
 Table 70. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)
 Table 71. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)
 Table 72. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)
 Table 73. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)
 Table 74. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)
 Table 75. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)
 Table 76. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)
 Table 77. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)
 Table 78. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)
 Table 79. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)
 Table 80. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)
 Table 81. Idiopathic Pulmonary Fibrosis (IPF) Drug Raw Material
 Table 82. Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug Raw Materials
 Table 83. Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Distributors
 Table 84. Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Customers


List of Figures
 Figure 1. Idiopathic Pulmonary Fibrosis (IPF) Drug Picture
 Figure 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Type, (USD Million), 2020 & 2024 & 2031
 Figure 3. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type in 2024
 Figure 4. Nintedanib Examples
 Figure 5. Pirfenidone Examples
 Figure 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Figure 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application in 2024
 Figure 8. Hospital Examples
 Figure 9. Clinics Examples
 Figure 10. Others Examples
 Figure 11. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value, (USD Million): 2020 & 2024 & 2031
 Figure 12. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value and Forecast (2020-2031) & (USD Million)
 Figure 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (2020-2031) & (K Units)
 Figure 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (2020-2031) & (US$/Unit)
 Figure 15. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Manufacturer in 2024
 Figure 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Manufacturer in 2024
 Figure 17. Producer Shipments of Idiopathic Pulmonary Fibrosis (IPF) Drug by Manufacturer Sales ($MM) and Market Share (%): 2024
 Figure 18. Top 3 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer (Revenue) Market Share in 2024
 Figure 19. Top 6 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer (Revenue) Market Share in 2024
 Figure 20. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Region (2020-2031)
 Figure 21. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Region (2020-2031)
 Figure 22. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 23. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 24. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 25. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 26. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 27. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)
 Figure 28. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Type (2020-2031)
 Figure 29. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2020-2031) & (US$/Unit)
 Figure 30. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)
 Figure 31. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application (2020-2031)
 Figure 32. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2020-2031) & (US$/Unit)
 Figure 33. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)
 Figure 34. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)
 Figure 35. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Country (2020-2031)
 Figure 36. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Country (2020-2031)
 Figure 37. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 38. Canada Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 39. Mexico Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 40. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)
 Figure 41. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)
 Figure 42. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Country (2020-2031)
 Figure 43. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Country (2020-2031)
 Figure 44. Germany Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 45. France Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 46. United Kingdom Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 47. Russia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 48. Italy Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 49. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)
 Figure 50. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)
 Figure 51. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Region (2020-2031)
 Figure 52. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Region (2020-2031)
 Figure 53. China Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 54. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 55. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 56. India Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 57. Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 58. Australia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 59. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)
 Figure 60. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)
 Figure 61. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Country (2020-2031)
 Figure 62. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Country (2020-2031)
 Figure 63. Brazil Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 64. Argentina Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 65. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)
 Figure 66. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)
 Figure 67. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Country (2020-2031)
 Figure 68. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Country (2020-2031)
 Figure 69. Turkey Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 70. Egypt Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 71. Saudi Arabia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 72. South Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)
 Figure 73. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers
 Figure 74. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints
 Figure 75. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Trends
 Figure 76. Porters Five Forces Analysis
 Figure 77. Manufacturing Cost Structure Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug in 2024
 Figure 78. Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug
 Figure 79. Idiopathic Pulmonary Fibrosis (IPF) Drug Industrial Chain
 Figure 80. Sales Channel: Direct to End-User vs Distributors
 Figure 81. Direct Channel Pros & Cons
 Figure 82. Indirect Channel Pros & Cons
 Figure 83. Methodology
 Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Roche Holding AG
Boehringer Ingelheim International GmbH

Related Reports

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2023-2029

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2023-2029

date 06 Sep 2023

date Pharma & Healthcare

The global Idiopathic Pulmonary Fibrosis (IPF) Drug market size is expected to reach $ 393.2 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 06 Sep 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at USD 298.4 million in 2022 and is forecast to a readjusted size of USD 393.2 million by 2029 with a CAGR of 4.0% during review period.

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 29 Feb 2024

date Pharma & Healthcare

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2024-2030

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2024-2030

date 29 Feb 2024

date Pharma & Healthcare

Product Tags

Idiopathic Pulmonary Fibrosis (IPF) Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>